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Abstract
Promoting angiogenesis is a key therapeutic target for protection from chronic ischemic cardiac 
injury. Endothelial-Monocyte-Activating-Polypeptide-II (EMAP II) protein, a tumor-derived 
cytokine having anti-angiogenic properties in cancer, is markedly elevated following myocardial 
ischemia. We examined whether neutralization of EMAP II induces angiogenesis and has 
beneficial effects on myocardial function and structure after chronic myocardial infarction (MI). 
EMAP II antibody (EMAP II AB), vehicle, or non-specific IgG (IgG) was injected ip at 30 min 
and 3, 6, and 9 days after permanent coronary artery occlusion in mice. EMAP II AB, compared 
with vehicle or non-specific antibody, significantly, p<0.05, improved the survival rate after MI, 
reduced scar size and attenuated the development of heart failure, i.e., left ventricular ejection 
fraction was significantly higher in EMAP II AB group, fibrosis was reduced by 24%, and 
importantly, more myocytes were alive in EMAP II AB group in the infarct area. In support of an 
angiogenic mechanism, capillary density (193/HPF vs. 172/HPF), doubling of the number of 
proliferating endothelial cells, and angiogenesis related biomarkers were upregulated in mice 
receiving EMAP II AB treatment as compared to IgG. Furthermore, EMAP II AB prevented 
EMAP II protein inhibition of in vitro tube formation in HUVECs. We conclude that blockade of 
EMAP II induces angiogenesis and improves cardiac function following chronic MI, resulting in 
reduced myocardial fibrosis and scar formation and increased capillary density and preserved 
viable myocytes in the infarct area.
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1. Introduction
Myocardial infarction (MI), caused by coronary artery disease, is the leading cause of 
morbidity and mortality in the United States. After coronary artery occlusion, the recovery 
of myocardial function is largely dependent on the heart’s ability to re-vascularize the peri-
infarcted region. Growth factors such as vascular endothelial growth factor (VEGF) were 
found to be important in promoting angiogenesis within the peri-infarcted region[1–6]. 
Consequently, angiogenesis has been studied as a promising therapeutic target in ischemic 
cardiovascular disease for some time, but despite the huge amount of data supporting this 
mechanism in experimental settings, little has moved forward to clinical therapy, making the 
discovery of novel pro-angiogenic mechanisms critical.
Accordingly, we studied a novel candidate, an EMAP II antibody, which blocks the 
Endothelial-Monocyte-Activating-Polypeptide-II (EMAP II) mediated pathway. EMAP II is 
a tumor-derived pro-inflammatory cytokine with anti-angiogenic properties[7–13] and 
inhibits VEGF-induced pro-angiogenic signaling in human umbilical vein endothelial cells 
(HUVEC)[14], making it an important target for retarding tumor progression [15–18]. In the 
heart, EMAP II protein expression was increased 24hrs after MI and remained elevated for 6 
weeks after MI [19]. If this intrinsic mechanism could be neutralized, it might provide a 
novel angiogenic mechanism, and protect ischemic myocardium. Indeed, after permanent 
CAO in hearts without preformed collaterals, angiogenesis is essentially the only 
mechanism to protect the ischemic myocardium. Therefore the goal of the present 
investigation was to determine in a mouse MI model, induced by permanent coronary artery 
occlusion (CAO), whether blocking the EMAPII pathway with an EMAP II neutralizing 
antibody induces angiogenesis and protects cardiac function after permanent CAO.
2. Materials and Methods
2.1 Surgical animal model of myocardial infarction
We performed left anterior descending (LAD) coronary artery occlusion (CAO) in 3–6 
month-old male C57BL/6 mice for myocardial infarction (MI). Briefly, mice were 
anesthetized with pentobarbital sodium (60 mg/kg, ip). The left side of the chest was 
opened, and the LAD artery was permanently ligated with 8-0 prolene suture through the 
third intercostal space incision under proper ventilation. Regional ischemia was confirmed 
by visual inspection (color change) and ECG monitoring (ST elevation). Sham-operated 
control mice underwent the same procedure without CAO. Animals used in this study were 
maintained in accordance with the Guide for the Care and Use of Laboratory Animals 
(National Research Council, Eighth Edition 2011). These studies were approved by the 
Institutional Animal Care and Use Committee in the New Jersey Medical School.
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2.2 EMAP II Antibody (AB) treatment
We used a rabbit anti-EMAP II (rEMAP II) antibody (polyclonal monospecific antibody 
based on immunoblotting of plasma and cell extracts; anti-EMAP II IgG blocked the activity 
of rEMAP II in cell culture assays) [19]. EMAP II antibody was produced as previously 
described [20]. In brief, a peptide sequence of 13 amino acid residues located within a 
homologous region of the human and murine forms of mature EMAP II were used to 
generate an antibody. This peptide was synthesized and the antibody produced by Zymed 
Laboratories, Inc. The antibody is specific to EMAP II identified by producing a single band 
on a western blot that is blocked after being incubated with excess EMAP II. In addition, the 
antibody used in these publications and in these studies is from a single rabbit and was 
protein A purified and sterile filtered. EMAP II dosing and injection interval of EMAP II 
antibody treatment is based on 125I EMAP II antibody labeled clearance studies as 
previously described [20]. Functionality of the antibody from a single rabbit was validated 
in vitro in a lung co-culture system markedly increased endothelial cell growth and tube 
formation [21] and in vivo [20]. Mice were selected randomly for treatment with either 
vehicle (rabbit IgG) or EMAP II AB (2mg/kg) via intraperitoneal injection by an 
investigator who was not involved in the surgery. EMAP II AB was injected at 30 min, day 
3, day 6, and day 9 after CAO surgery.
2.3 Measurement of cardiac function by echocardiography
To measure LV function, two-dimensional transthoracic echocardiography was performed in 
mice using ultrasonography (Accuson 256, Siemens Medical Solutions) with a 13-MHz 
linear ultrasound transducer under anesthesia with 1.25 % Tribromoethanol (Avertin, 290 
mg/kg, ip) Measurement of LV end-diastolic and end systolic diameters and wall thickness 
and LV ejection fraction and fractional shortening were taken from the myocardium 
proximal to the infarct. Following echocardiography, the heart tissue was harvested after the 
mice were euthanized using CO2 inhalation.
2.4 Measurement of capillary density and proliferating endothelial cells (ECs)
Four weeks after CAO, the heart was immediately excised, fixed with 10% neutralized 
buffered formalin and embedded in paraffin for histological studies. 5μm thickness of serial 
heart tissue sections were used for histological assessment and immunohistochemical 
staining. In order to discriminate proliferation in non-myocytes and myocytes, tissue 
sections were counterstained with wheat germ agglutinin (WGA) Alexa Fluor-488 conjugate 
(Invitrogen) or troponin I, a myocyte marker, as described in our previous study [22].
For measurement of capillary density, ECs were stained with isolectin-IB4 from Griffonia 
simplicifolia (InVitrogen), and quantitative analysis was accomplished using Image-Pro Plus 
software after taking pictures under 40×magnification with an Olympus microscope. 
Relative capillary density was calculated as capillary numbers/HPF (high power field).
Tissue sections were double-immunostained with rabbit-anti Ki67 antibody (Neomaker) or 
anti-phosphohistone H3 (PHH3) (Cell Signaling) as a proliferation marker with isolectin-IB4 
as an EC marker. Antigen retrieval was performed in 10mM citrate buffer (pH 6.0) with 
boiling under pressure for 10 min. After the blocking process with Protein Block Serum-
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Free solution (DAKO), the tissue sections were incubated with Ki67 or PHH3 for 1hr at 
37°C followed by detection with goat anti-rabbit Alexa 594 conjugated (Invitrogen). The 
myocardium was further incubated with isolectin-IB4 Alexa Fluor-488 conjugated antibody 
(Invitrogen) overnight at 4°C. Sections were mounted using ProLong Gold antifade reagent 
with DAPI (Invitrogen). The proliferation of ECs were expressed as the number of 
Ki67+Isolectin+ cells per mm2 or PHH3+isolectin+ cells per mm2. Vessels in the infarct 
area were immunostained with α-smooth muscle actin (α-SMA) (Abcam). Only vessels with 
ring structure were counted to distinguish arterial vessels from myofibroblasts, which also 
stain with α-SMA.
2.5 In vitro EC tube formation assay
Human microvascular endothelial cells from the heart (HMVEC-Cs) were purchased from 
Lonza (Basel, Switzerland). Human umbilical vein endothelial cells (HUVECs) were 
purchased from ATCC (Manassas, VA, USA). Matrigel (reduced growth factor, BD 
Bioscience) was placed in 12-well tissue culture plates allowed to gel at 37°C for 30 min. 
Cells were cultured on the Matrigel with either vehicle (rabbit nonspecific IgG 1μM), 
EMAP II protein (1μM), or EMAP II AB (1μM) treatment for 20hrs. For an hypoxic 
condition, cells were incubated in a hypoxia chamber for 5hrs.
2.6 Measurement of interstitial fibrosis
To examine the collagen deposition after MI, tissue sections were stained with Picric acid 
Sirius Red (PSR) after 1 and 4 weeks with vehicle or EMAP II AB treatment. Quantitative 
analysis of interstitial fibrosis was accomplished using Image-Pro Plus software after taking 
pictures under an Olympus microscope at 20× magnification.
2.7 Measurement of scar size after chronic MI
For measuring scar size after 4weeks MI, LV was cross-sectioned at two levels below the 
coronary artery ligation position, and paraffin-embedded. Each level of tissue was divided 
by five sub-levels, and a 5μm serial cut was performed. Tissue slides were stained with PSR 
and scar size was measured with ImageJ software. For measuring viable myocytes in the 
infarcted area after 4wks MI, LV was stained with troponin I, with isolectin-IB4 and DAPI 
after longitudinal-sectioning of the heart with a four chamber-view. The number of viable 
myocytes in the infarct area was determined by counting troponin I + myocytes in the infarct 
area.
2.8 Myocyte size and number
To measure myocyte cross-sectional area, tissue sections were co-stained with WGA and 
DAPI, and quantitated using ImagePro-Plus software. The total number of myocytes of each 
group was measured by the method of Kajstura et al.[23].
2.9 Quantitative RT-PCR
Specific primers and probes (derived with FAM and TAMRA, ordered from IDT DNA 
Company) were designed for the transcripts of interest. The optimal combination of primers 
and probes for a qPCR assay was determined with the Primer Express software (Applied 
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Biosystems). Following reverse transcription of the mRNA of interest from 50ng of total 
RNA, the cDNA was used for quantitative PCR (qPCR) (40 cycles of a 10-s step at 95°C 
and a 1-min step at 60°C) using the SybrGreen method on a 7700 ABI-Prizm Sequence 
Detector (Applied Biosystems, Foster City, CA). Values are reported per 18s rRNA 
transcript to correct for sample-to-sample RNA loading variations.
Genes and primer sequences used in this study:
Gene Forward (5′ 3′) → Reverse (5′ 3′) →
Rn18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGC
Ephb2 GCCGTGGAAGAAACCCTGAT GTTCATGTTCTCGTCGTAGCC
Ephb4 GGAAACGGCGGATCTGAAATG TGGACGCTTCATGTCGCAC
Cdh1 CAGTTCCGAGGTCTACACCTT CCAGGACATGGCCTCTCTC
Icam1 CGCTGTGCTTTGAGAACTGTG ATACACGGTGATGGTAGCGGA
Vcam1 TTGGGAGCCTCAACGGTACT GCAATCGTTTTGTATTCAGGGGA
Itga5 TGCAGTGGTTCGGAGCAAC TTTTCTGTGCGCCAGCTATAC
Vegfa CTGCCGTCCGATTGAGACC CCCCTCCTTGTACCACTGTC
Pecam1 ACGCTGGTGCTCTATGCAAG GTGAAGGAGTTTTCCTCAGCC
Kdr TTTGGCAAATACAACCCTTCAGA GCTCCAGTATCATTTCCAACCA
2.10 Western blot
Western blot was performed to determine the time course of EMAP II expression after MI as 
previously described [1]. Briefly, tissue was obtained from the same region in the heart in 
every animal, rinsed in 50mM Tris pH 7.4, 0.9 N NaCl, and 0.01% NaN3, homogenized in 
the presence of proteinase inhibitors. The homogenates were cleared by centrifugation at 
14,000 g for 20 min; the protein concentration was determined by Bradford analysis (Bio-
Rad, CA), and the samples were normalized by protein content. Equal amounts of protein 
were electrophoresed on a 12% SDS–PAGE gel, transferred to a nitrocellulose membrane. 
After blocking with 5% milk for 1 hour, the membrane was probed with a rabbit anti-EMAP 
II antibody (1:200) at 4°C for 1 hour, rinsed with TBST X3, then probed with HRP 
conjugated anti-rabbit secondary antibody (1:10000, Bio-Rad, CA). Specific binding was 
detected using a chemiluminescence substrate (Pierce, Rockford, IL) and blue basic autorad 
film (BioExpress, Belgium). Quantitative analysis was accomplished using a GS-800 
calibrated densitometer (Bio-Rad, CA).
2.11 Statistical analysis
All data are expressed as mean ±SE. Comparisons between vehicle and the EMAP II AB 
treated groups were performed by the Student’s t-test. For statistical analysis of data from 
multiple groups, we used ANOVA followed by the Student-Newman-Keuls or Bonferroni 
post hoc analysis. For data that did not meet the ANOVA assumptions, the Kruskal-Wallis 
test was applied using GraphPad-Prism 5.0 (GraphPad-Software, San Diego, CA). The data 
for uncensored survival time was analyzed using the Wilcoxon and the log-rank test. p<0.05 
was taken as a minimal level of significance.
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3. Results
3.1 EMAP II protein was increased in the heart after MI
Previous studies in the rat heart have shown that EMAP II protein expression was increased 
24hrs after MI and remained elevated for 6 weeks post MI10. To confirm that EMAP II 
protein expression was also induced by MI in the mouse heart, we did a time course study of 
EMAP II expression after MI. As shown in Figure 1C, EMAP II protein expression was 
increased, p<0.05, by 1.9 fold 24 hours after MI in the mouse heart, and remained elevated, 
p<0.05, at 1 week (1.3 fold), 2 weeks (1.5 fold) and 4 weeks (1.2 fold).
3.2 EMAP II AB significantly improved the survival rate after MI
To test whether EMAP II AB increased survival of mice after chronic myocardial infarction 
(MI), permanent CAO was induced in 3–6 month-old male C57BL/6 mice, either treated 
with vehicle (rabbit IgG) or EMAP II AB (2 mg/kg) via intraperitoneal injection. EMAP II 
AB was injected at 30 min, day 3, day 6 and day 9 after CAO. As shown in Figure 1A, the 
Kaplan-Meyer survival study indicated that the survival rate in mice treated with EMAP II 
AB was significantly improved after MI.
3.3 EMAP II AB protected cardiac function after MI
Blockade of EMAP II improved LV systolic function after chronic MI induced by 
permanent CAO: LV ejection fraction and fractional shortening were not different in sham 
animals treated with vehicle or EMAPII AB. LV ejection fraction was reduced significantly 
more (p<0.05) in the vehicle group at 1 week (53±2.2%) and 4 weeks (35±2.4%) after MI 
than in the EMAP II AB group (61±1.2% at 1 week and 53±4.4% at 4 weeks, respectively) 
from baseline values in sham operated mice (72±0.5%, n=4) (Figure 1B and Table 1). 
Fractional shortening was also significantly improved in the EMAP II AB group compared 
to the vehicle group, by levels similar to those for LV ejection fraction after 4 weeks MI 
(Table 1). Heart weight/tibial length (HW/TL) was not different in sham animals treated 
with vehicle or EMAPII AB. At 4 wks after MI, HW/TL was slightly, but not significantly 
greater in the EMAPII treated mice (8.3±0.4) compared with those receiving vehicle 
(8.0±0.2), potentially due to the increased numbers of myocytes in the MI zone. Lung 
weight/TL was not different in either sham or after 4 wks MI in the two groups. It is 
important to recognize that the beneficial effects of EMAP II AB on LV function after 
chronic MI would have been even more dramatic, if all animals had survived, since those 
that died (more in the vehicle group) most likely had worse LV function.
3.4 EMAP II AB reduced fibrosis and scar size and preserved myocytes after MI
We then explored the underlying histological changes after EMAP II AB treatment. The scar 
size was decreased, p<0.05, after 4wks MI with the EMAP II AB (20.8±6.2%, n=6) 
compared with the vehicle group (32±7.9%, n=6) as shown by PSR staining (Figure 2A). 
Fibrosis adjacent to the infarct was also reduced in the EMAP II AB group, compared with 
the vehicle group at both 1 and 4 weeks after MI (Figure 2B). The number of viable 
myocytes in the infarct area was determined by counting troponin I+ myocytes in the infarct 
area. More preserved myocytes were seen in the EMAP II AB group in the infarct area, 
Yuan et al. Page 6
J Mol Cell Cardiol. Author manuscript; available in PMC 2016 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
shown with H&E staining, after 4wk MI (Figure 3A). We used double immunostaining of 
Ki67 as a proliferation marker, and WGA as a myocyte marker, and DAPI to identify the 
nucleus, to study whether blockade of EMAP II affects the number of proliferating 
myocytes after MI. Proliferating myocytes were increased with EMAP II AB as shown in 
Figure 3B.
3.5 EMAP II AB increased angiogenesis after chronic MI
We then used double immunostaining of Ki67 or phosphohistone H3 (PHH3) as 
proliferation markers, and isolectin-IB4 as an endothelial cell (EC) marker to study whether 
blockade of EMAP II affects angiogenesis after MI. Using immunostaining of CD 34 as an 
endothelial progenitor cell marker, vWF as a vessel endothelial cell marker, we found that 
the progenitor endothelial cells were increased after EMAP II AB treatment (Figure 4A). 
The number of Ki67-positive EC was also increased in the EMAP II AB group compared to 
vehicle after 4 week MI (Figure 4B). The EMAP II AB group showed increased capillary 
density in the non-ischemic zone of the heart compared to vehicle (193±5/HPF vs. 172±4/
HPF) (n=5), p<0.05 (Figure 4C). EMAP II AB treatment also increased the number of blood 
vessel smooth muscle cells after chronic MI (Figure 4D).
3.6 EMAP II AB promotes angiogenesis in vitro
Finally, we used an in vitro tube formation model to confirm that EMAP II AB could 
promote angiogenesis. HMVEC-Cs were cultured on the Matrigel with vehicle or EMAP II 
AB treatment for 20hrs. Hypoxia, where cells were incubated in a hypoxia chamber for 5 
hours, was used to mimic in vivo MI. As shown in Figure 5A, EMAP II AB significantly 
increased tube formation as compared with vehicle. Next, to confirm this and also to more 
closely mimic the in vivo condition, we used EMAP II protein to see whether it could inhibit 
in vitro tube formation, and whether EMAP II AB could reverse the anti-angiogenic effect 
of EMAP II protein. As shown in Figure 5B, EMAP II protein did inhibit the in vitro tube 
formation, and this phenomenon was reversed by EMAP II AB, indicating that the 
protective role of EMAP II AB was through its neutralization of the anti-angiogenic effect 
by EMAP II protein. Most of angiogenesis related biomarkers were also upregulated after 
EMAP II AB treatment (Figure 6). These results strongly suggest that the beneficial effects 
of EMAP II AB after chronic CAO are due to enhanced angiogenesis.
4. Discussion
In hearts without preformed collateral vessels, it is almost impossible to protect the ischemic 
myocardium in the absence of angiogenesis. In this study, we found that EMAP II AB 
reduced MI scar size and significantly improved the survival rate and cardiac function after 
chronic MI through an EMAP II angiogenic mechanism. EMAP II is an anti-angiogenic 
protein that has been identified in the myocardium during fetal development [24], and has 
been shown to inhibit metastatic tumor growth with its anti-angiogenic properties [15, 17, 
18, 20]. Furthermore, EMAP II was shown to be expressed with transcription products 
localizing predominantly to the perivascular stroma region in the normal rat myocardium 
and was upregulated 2-fold in the heart 6 hours following MI and remained elevated 
following MI in the peri-infarct region [19].
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The underlying hypothesis of this study was that blocking the anti-angiogenic properties of 
EMAP II after MI would result in increased angiogenesis, which would in turn protect the 
heart against the development of heart failure after MI. Indeed, the mice treated with EMAP 
II antibody exhibited reduced mortality from MI (Figure 1A) and protected the ischemic 
heart, as reflected by reduced infarct scar and adjacent fibrosis resulting in a significant 
preservation of cardiac function.
The reduced scar and preservation of cardiac function were most likely due to the 
angiogenesis that was induced by the EMAP II antibody, as demonstrated by increased 
capillary density, upregulated angiogenesis related biomarkers and increased vessel tube 
formation in vitro, which has also been demonstrated in developmental models [20, 21]. 
Furthermore, we have previously reported that inhibition of VEGF signaling is one possible 
anti-angiogenic mechanism of EMAP II [14]. In that report, we showed that EMAP II 
protein efficiently and dose dependently binds to VEGF receptor 1 (VEGFR1) and VEGF 
receptor 2 (VEGFR2). In addition, EMAP II protein inhibited binding of VEGF to VEGFR1 
and VEGFR2. In the current study, we did a comprehensive qPCR study of angiogenesis 
markers and determined that most of these markers, such as VEGFA and VEGFR2 (KDR), 
were significantly up-regulated after treatment with a neutralizing EMAP II AB treatment, 
but not nonspecific IgG, as shown in Figure 6. An in vitro vessel tube formation study with 
HMVEC-Cs cultured under hypoxia, showed that EMAP II AB significantly increased tube 
formation as compared with vehicle (Figure 5A). In addition, we examined in vitro vessel 
formation with HUVEC cells treated with either EMAP II protein, EMAP II AB, EMAP II 
protein + EMAP II AB, or EMAP II protein + nonspecific IgG. We found that EMAP II 
protein significantly inhibited vessel formation, and this inhibition could be neutralized and 
rescued by EMAP II AB, but not by nonspecific IgG, as shown in Figure 5B. This supports 
the concept that VEGF mediated angiogenesis is a key mechanism of action of EMAP II AB 
neutralization of EMAP II protein.
As a further result of the angiogenesis, the infarct area after 4 week MI demonstrated 
significantly more viable myocytes in the EMAP II AB group than in the vehicle group, as 
assessed by dual staining with troponin I and isolectin-IB4. The numbers of proliferating 
myocytes were also increased at both 1 and 4 weeks after MI, as assessed by Ki67 [25, 26]. 
Myocyte regeneration and proliferation are controversial topics [27–32]. On one hand 
several investigators report that this mechanism is important to repairing the infarcted heart 
[33–38]. On the other hand others have reported that this mechanism does not occur [39, 
40]. One other point of view is that it occurs but just at lower levels [41, 42]. Although it 
could be argued whether or not myocyte regeneration or proliferation occurred in the present 
study, it is clear that the numbers of Ki67 positive myocytes did increase in the ischemic 
zone of the mice treated with EMAP II antibody, and most importantly, the numbers of 
myoctes within the ischemic zone were significantly greater in those animals with antibody 
treatment.
In summary, neutralization of the anti-angiogenic cytokine, EMAP II, preserved LV 
function by promoting angiogenesis with reduction of scar size and fibrosis, and 
preservation of myocytes in the infarct area after chronic MI. Since EMAP II increases 
naturally during chronic MI, it could play a role in limiting angiogenesis with chronic 
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myocardial ischemia and conversely, blocking this adverse effect could be a potential novel 
therapeutic target for chronic myocardial ischemic disease.
5. Conclusion
Neutralization of EMAP II induces angiogenesis and improves cardiac function following 
chronic MI, resulting in reduced myocardial fibrosis and scar formation and increased 
capillary density and most importantly, preserved viable myocytes in the infarct area.
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Highlights
1. First in vivo study showing that blockade of EMAP II by a neutralizing antibody 
significantly improved survival rate after chronic myocardial infarction
2. Blockade of EMAP II improves cardiac function following chronic myocardial 
infarction, resulting in reduced myocardial fibrosis and scar formation.
3. The underlying EMAP II mechanism involves angiogenesis as demonstrated 
both in vitro and in vivo.
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Figure 1. 
EMAP II AB promotes survival and preserves heart function after chronic myocardial 
infarction (MI). (A) Kaplan-Meyer survival curve of mice treated with either EMAP II AB 
or vehicle after 4 week chronic MI. *: p<0.05 compared with vehicle, n=30 for EMAP II AB 
group, n=28 for vehicle group. (B) EMAP II AB treated mice have preserved left ventricle 
ejection fraction after both 1 and 4 weeks chronic MI. *:p<0.05 compared with vehicle, 
n=10 for EMAP II AB group, n=7 for vehicle group. (C) Dynamics of EMAPII expression 
after chronic MI. EMAP II expression was upregulated one day after MI surgery and 
continues to be highly expressed at least two weeks after MI as shown with representative 
western blot (top panel) and quantification (bottom panel). **: p<0.01, *: p<0.05, all 
compared with Sham.
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Figure 2. 
EMAP II AB improved LV structure with reduced scar size and collagen deposition. (A) The 
scar size was decreased after EMAP II AB treatment for 4 weeks. Upper panels: 
Representative images of infarct rings after 4wk MI as shown by PSR staining; lower panel: 
quantitative data. (B) The interstitial fibrosis (%) in the adjacent area was less in the EMAP 
II AB group after both 1 and 4 week MI as shown by PSR staining. Upper panels: 
representative images after 1 wk MI; lower panel: quantitative data.
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Figure 3. 
EMAP II AB preserved myocytes and increased proliferating myocytes after chronic MI. (A) 
More preserved myocytes were seen in EMAP II AB as shown with H&E staining of infarct 
area after 4 week MI. Left panels: H&E staining images (original magnification, ×10); right 
panel: quantitative data. (B) Proliferating myocytes were increased with EMAP II AB as 
shown by Ki67-WGA-DAPI triple staining (left panel) and quantification (right panel). *: 
p<0.05 compared with vehicle. n=6 for each group.
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Figure 4. 
EMAP II AB increased angiogenesis after chronic MI. (A) EMAP II AB increased 
progenitor ECs as shown by increased numbers of vWF+ and CD34+ endothelial cells. Left 
panels: vWF and CD34+ staining images; right panel: quantitative data. (B) EMAP II AB 
increased proliferating ECs as shown by representative photographs of Ki67+ endothelial 
cells (left panel) and quantification (right panel). (C) EMAP II AB increased capillary 
density. (D) EMAP II AB also increased blood vessel smooth muscle cells after chronic MI. 
*: p<0.05 compared with vehicle. n=5 for each group.
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Figure 5. 
EMAP II AB promotes angiogenesis demonstrated with in vitro tube formation assay. (A) 
EMAP II AB stimulates more tube formation in cultured HMVEC-Cs under hypoxia as 
shown by representative photographs (left panel; original magnification, ×10) and 
quantification (right panel). *:p<0.05 compared with vehicle (B) EMAP II protein inhibited 
tube formation in culture HUVECs which could be rescued by EMAP II AB. as shown by 
representative photographs (upper panel) and quantification (lower panel). **:p<0.01 
compared with no treatment; #: p<0.05 compared with EMAP II protein; +:p<0.05 
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compared with EMAP II protein + vehicle. Data presented are representative of experiments 
repeated independently three times.
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Figure 6. 
EMAP II AB upregulated angiogenesis related biomarkers after chronic MI as determined 
by quantitative PCR. Results are expressed as the mean ± SEM. *: p<0.05 compared with 
vehicle, **: p<0.01 compared with vehicle. n=5 per group.
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Table 1
Echocardiographic Data
Sham 4 wk MI
Vehicle + EMAPII Vehicle EMAP-II AB
 n 8 7 10
LV EF (%) 72 ± 1.0 35 ± 2.4* 53 ± 4.4*†
LV FS (%) 35 ± 0.8 13 ± 1.1* 23 ± 2.4*†
LVEDD(mm) 3.84 ± 0.05 5.51 ± 0.31* 5.25 ± 0.22*
LVESD(mm) 2.51 ± 0.05 4.78 ± 0.29* 4.08 ± 0.25*
Heart Rate (bpm) 440 ± 5 400 ± 18 375 ± 13*
*p<0.05 vs. Sham
†p<0.05 vs. Vehicle after 4wk MI
(One way ANOVA with Bonferroni post hoc analysis)
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